4月21日,中国国家药监局药品审评中心(CDE)官网最新公示,由百时美施贵宝公司申报的瑞普替尼胶囊新适应症上市申请已获得受理。瑞普替尼(repotrectinib)是靶向作用于ROS1及NTRK致癌驱动基因的新一代酪氨酸激酶抑制剂(TKI),再鼎医药拥有该产品在大中华区的独家开发及商业化权。根据再鼎医药新闻稿可知,该药本次申报上市的适应症为:用于治疗携带神经营养酪氨酸受体激酶(NTRK)基因融合的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.